Five Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements

CORAL SPRINGS, Florida, July 27, 2016 /PRNewswire/ --

With research and development being pivotal in the advancing treatments for rare diseases and conditions, companies in the biotech sector aim to remain competitive through continued R&D activities, introduction of latest biomedical therapies and mergers & acquisitions.

SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Q BioMed Inc.  (OTCQB: QBIO) with a price target of $3.85.  The report is available here: http://www.seethruequity.com/#!qbio/cxnb   

QBIO is focused on identifying, acquiring and licensing attractive biomedical assets from small private companies and academia, which lack the resources and experience to bring their programs to market on their own.  QBIO believes it can add considerable value to its investments by providing strategic capital, industry resources and experience in order to accelerate the development and commercialization of life science assets.  QBIO's initial program is MAN-01, a small molecule designed to treat glaucoma, an eye disease which affects 60mn people globally, and is expected to affect over 100mn people by 2020E.  The glaucoma market is a $5 billion annual market opportunity, for which no new drugs have been approved in approximately 20 years.  The company acquired an exclusive license to MAN-01 from Mannin Research, Inc. The technology platform is based on the research of Dr. Susan Quaggin, Chief Scientific Officer of Mannin Research. Broadly, Dr. Quaggin's research demonstrates a unique approach to treating a host of vascular diseases including glaucoma, cystic kidney disease, influenza, ebola, and others.  These additional indications are part of the exclusive license agreement with Mannin.  In addition to the Mannin Research platform technology, QBIO has announced its intention to acquire 2-3 additional programs over the next twelve months.

Read the full Q BioMed (OTC: QBIO) release at: http://financialnewsmedia.com/profiles/qbio.html

"In our view the experience and quality of management should a crucial role in the successful execution of the biomedical accelerator model.  Indeed, the core value promised by QBIO is that it will be able to identify, develop, and support value-creating programs harvested from small private biomedical companies and academia, providing a conduit which would otherwise be difficult to access or unavailable to pubic company investors - and then provide strategic capital and other valuable resources to these companies to help them reach commercialization and/or a value-creating event.  QBIO is led by CEO Denis Corin, who brings a wealth of experience in the biomedical field at both large pharmaceutical firms and small innovative firms in the biotech space," stated Ajay Tandon, CEO of SeeThruEquity. "We see serval potential catalysts for the company in coming months, including the pending acquisition of a new cancer palliation drug. We are initiating coverage with a price target of $3.85.

Q BioMed Inc. is to be featured on CEO Clips on The Documentary Channel as well as Thomson Reuters Insider Network at http://reut.rs/29TZ6Th.  CEO Clips, a series which profiles the most innovative publicly traded companies in North America, will feature QBIO on The Documentary Channel in August, Monday through Friday, throughout the day and evenings.

In other Biotech advancing leaders in the markets this week:  Cesca Therapeutics Inc. (NASDAQ: KOOL) closed up over 44% at $4.97 on Tuesdayon over 13.2Million shares traded by the market close.  Cesca Therapeutics focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine in the United States and internationally. The company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing, and cryopreservation of cell and tissue therapy products.

Alimera Sciences (NASDAQ: ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, pre-announced its revenue for the second quarter of 2016 and also announced certain modifications to its loan facility.  Second quarter 2016 revenue is expected to be in the range of $9.3 million to $9.5 million, representing sequential growth of more than 50% over the first quarter of 2016 and growth in excess of 50% over the second quarter of 2015. Second quarter 2016 U.S. revenue is expected to be in the range of $7.0 million to $7.2 million, representing sequential growth of more than 65% over the first quarter of 2016 and growth in excess of 75% over the second quarter of 2015.  ALIM closed up over 59% at $1.69 on over 16.2Million shares traded by the market close on Tuesday.

Exact Sciences Corp. (NASDAQ: EXAS) announced that the company generated revenues of $21.2 million during the second quarter ended June 30, 2016, representing a 161-percent increase from $8.1 million in the second quarter of 2015. The company completed approximately 54,000 Cologuard tests during the second quarter, an increase of approximately 160 percent compared to the 21,000 tests completed during the same period of 2015. Since Cologuard's launch and through the end of the second quarter of 2016, approximately 41,000 physicians have ordered the test.  EXAS closed up over 30% at $16.21 on over 29.3 Million shares traded by the market close on Tuesday.

Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, recently announced that it has received patents issued by the U.S. Patent and Trademark Office (USPTO), the European Patent Office (EPO) and the Korean Intellectual Property Office (KIPO) covering the Company's lead hemostasis programs, next-generation coagulation Factor VIIa and Factor IX, and the Company's anti-complement program. These patents build on the Company's extensive portfolio that now totals 103 patents issued world-wide.  EXAS closed up over 13% at $1.56 on over 1.4 Million shares traded by the market close on Tuesday.

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at financialnewsmedia.com.  Follow us on Facebook: facebook.com/financialnewsmedia and Twitter: twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated three thousand seven hundred dollars for news coverage of the current press release issued by Q BioMed Inc. by the company.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  [email protected]

SOURCE FN Media Group LLC